Evolent Health, Inc.
For the period ended Mar 31, 2025. Filed May 9, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 9, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On March 12, 2025, Seth Blackley, the Company’s Chief Executive Officer and a member of the Company’s Board of Directors, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (the “Blackley Plan”). The first possible trade date under the Blackley Plan is September 8, 2025, and the end date of the Blackley Plan is January 30, 2026. The aggregate amount of securities that may be sold under the Blackley Plan is 300,505 shares.
On March 10, 2025, Daniel McCarthy, the Company’s President, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (the “McCarthy Plan”). The first possible trade date under the McCarthy Plan is September 8, 2025, and the end date of the McCarthy Plan is February 20, 2026. The aggregate amount of securities that may be sold under the McCarthy Plan is 128,080 shares.
On March 14, 2025, Emily Rafferty, the Company’s Chief Operating Officer, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (the “Rafferty Plan”). The first possible trade date under the Rafferty Plan is June 13, 2025, and the end date of the Rafferty Plan is March 31, 2026. The aggregate amount of securities that may be sold under the Rafferty Plan is 10,000 shares.
On March 13, 2025, Jonathan Weinberg, the Company’s General Counsel, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (the “Weinberg Plan”). The first possible trade date under the Weinberg Plan is June 12, 2025, and the end date of the Weinberg Plan is December 31, 2025. The aggregate amount of securities that may be sold under the Weinberg Plan is 19,755 shares.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.